Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | KMO | O15229 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30882116 | 1.00 | HPGD (0.50) | HPGDSLC6A4HTR6MCHR1KMO | |
| SCHEMBL22069677 | 0.97 | HPGD (0.50) | HPGDSLC6A4HTR6MCHR1KMO | |
| SCHEMBL2562599 | 0.93 | KMO (0.47) | HPGDSLC6A4HTR6KMOHTR2C | |
| SCHEMBL30781076 | 0.93 | KMO (0.47) | HPGDSLC6A4HTR6KMOHTR2C | |
| SCHEMBL19089352 | 0.86 | SCN9A (0.46) | HPGDMCHR1KMOHTR2CHTR2B | |
| SCHEMBL30140430 | 0.83 | HTR2C (0.37) | HPGDMCHR1KMOHTR2CHTR2B | |
| SCHEMBL30126151 | 0.81 | MCHR1 (0.49) | MCHR1HTR2CHTR2BSCN9AP2RX4 | |
| SCHEMBL30126836 | 0.81 | MCHR1 (0.49) | MCHR1HTR2CHTR2BSCN9AP2RX4 | |
| SCHEMBL30126942 | 0.81 | MCHR1 (0.49) | MCHR1HTR2CHTR2BSCN9AP2RX4 | |
| SCHEMBL20708624 | 0.81 | NPC1 (0.52) | HPGDHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820860-B1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-11993581-B2 | Pyridazine compounds for inhibiting Nav1.8 | LIEBER INSTITUE, INC (US) | 2024-05-28 | — | — | US | disclosed |
| EP-3820860-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | Lieber Institute, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN5A, SCN2A | HPGD 1577/4885SLC6A4 221/4885HTR6 362/4885 |
| US-11993581-B2 | Pyridazine compounds for inhibiting Nav1.8 | SCN8A, SCN5A, SCN2A | HPGD 1577/4885SLC6A4 221/4885HTR6 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.